Avalo Therapeutics, Inc.

NASDAQ:AVTX

Biotechnology

Healthcare
$6.70 -2.18%

-$0.34 today

Market cap
$387.41M
Beta
0.82
P/E (TTM)
-3.6
EPS (TTM)
-$4.21
52W Low $4.50High $24.27

Volume 1.58M

Average 1.61M

AVTX Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Avalo Therapeutics, Inc.NASDAQ: AVTX

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $17K fell 87.4% year over year, behind the -16.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 6.3% from the prior quarter. Over 3 fiscal years it compounded at +27.5% a year.

Context

  • Depreciation & amortization amounted to 583.1% of revenue in FY2025, up 544.7 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -87.4% toward the trailing-twelve-month pace of -16.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$17K+6.3% QoQ
Last fiscal yearDec 2025
$344K+103.6% YoY
LTMMar 2026
$226K-16.3% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-87.4%——
1 year+103.6%——
3-year CAGR+27.5%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
344K USD
Year-over-year change
+103.6%
4-year CAGR
-32.5%

Depreciation & Amortization vs competitors

How AVTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -16.3% is the 6th highest of 9, against a peer median of -4.8%.
  • Depreciation & amortization amounts to 383.1% of revenue for AVTX, versus a peer median of 3.7%.
AVTX Competitors
Depreciation & Amortization for AVTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
XNCRXencor, Inc.LTM Jun 2026$10.17M USD-10.7%+6.1%9.7%
ANABAnaptysBio, Inc.LTM Mar 2026$2.43M USD+1.2%+1.2%1.0%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$528K USD+7.3%-17.1%6.3%
IFRXInflaRx N.V.LTM Mar 2026€392.86K EUR-17.3%-11.1%1339.4%
QTTBQ32 Bio Inc.LTM Mar 2026$362K USD-25.1%+1.9%0.7%
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY2024€311K EUR+214.1%——
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$226K USD-16.3%+27.5%383.1%
IMUXImmunic, Inc.LTM Mar 2026$158K USD+4.6%+29.7%—
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026$81K USD-69.3%-5.7%—
SYRESpyre Therapeutics, Inc.LTM Sep 2026$0 USD—+72.0%0.0%
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding AVTX) —-4.8%+1.5%3.7%

Competitors are the stored peer set for AVTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue5.4M18.05M1.92M441K59K
Cost of Revenue1.49M3.43M1.28M(366K)0
Gross Profit3.91M14.62M640K807K59K
Gross Margin72.4%81.0%33.3%183.0%100.0%
Research & Development59.84M31.31M13.78M52.08M50.08M
Selling, General & Admin24.66M20.71M10.3M17.24M22.9M
Operating Expenses86.04M52.06M27.99M69.32M72.98M
Depreciation & Amortization1.66M166K158K169K344K
EBITDA(80.5M)(37.29M)(23.29M)(34.85M)(77.75M)
EBITDA Margin-1491.2%-206.6%-1210.3%-7901.6%-131779.7%
Operating Income(82.13M)(37.44M)(27.35M)(68.51M)(72.93M)
Operating Margin-1521.6%-207.4%-1421.6%-15535.6%-123601.7%
Interest Income0003.32M4.35M
Interest Expense2.39M4.17M3.42M00
Other Income / Expenses(2.41M)(4.19M)(4.18M)33.5M(5.17M)
Income Before Tax(84.55M)(41.63M)(31.53M)(35.02M)(78.09M)
Pre-Tax Margin-1566.2%-230.6%-1638.8%-7939.9%-132362.7%
Income Tax Expense(196K)28K14K114K165K
Net Income(84.38M)(41.66M)(31.54M)(35.13M)(78.26M)
Net Margin-1563.1%-230.8%-1639.5%-7965.8%-132642.4%
EPS (Basic)(2,330.66)(1,062.65)(113.58)(4.32)(5.84)
EPS (Diluted)(2,330.66)(1,062.65)(113.58)(3.26)(5.84)
Weighted Avg Shares36.19K39.2K277.73K8.13M13.4M
Weighted Avg Shares (Diluted)36.19K39.2K277.73K10.78M13.4M

Avalo Therapeutics, Inc.

NASDAQ:AVTX

Intrinsic Alpha fair value

Locked

Current Price

$6.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.